A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

被引：130

作者：

Tobinai, Kensei ^{[1
]}

Klein, Christian ^{[2
]}

Oya, Naoko ^{[3
]}

Fingerle-Rowson, Gunter ^{[4
]}

机构：

[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[2] Roche Innovat Ctr Zurich, Roche Pharmaceut Res & Early Dev, Schlieren, Switzerland

[3] Chugai Pharmaceut Co Ltd, Oncol Lifecycle Management Dept, Tokyo, Japan

[4] F Hoffmann La Roche Ltd, Pharma Dev Oncol, Basel, Switzerland

来源：

ADVANCES IN THERAPY | 2017年 / 34卷 / 02期

关键词：

Antibody-dependent cell-mediated cytotoxicity; B-cell lymphoma; CD20; Chronic lymphocytic leukemia; Glycoengineering; Monoclonal antibody; Non-Hodgkin lymphoma; Obinutuzumab; Oncology; Rituximab; CHRONIC LYMPHOCYTIC-LEUKEMIA; CLINICAL-PRACTICE GUIDELINES; FC-GAMMA-RIIB; FOLLICULAR LYMPHOMA; BISPECIFIC ANTIBODY; CD20; ANTIBODY; OPEN-LABEL; MEDIATED PHAGOCYTOSIS; PLUS CHLORAMBUCIL; CYTOKINE-RELEASE;

D O I：

10.1007/s12325-016-0451-1

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies. Efficacy as monotherapy has been reported in patients with relapsed/refractory indolent and aggressive non-Hodgkin lymphoma (NHL) and in chronic lymphocytic leukemia (CLL) of B-cell origin. Improved outcomes have also been noted when obinutuzumab is added to chemotherapy in patients with B-cell NHL, and superiority over rituximab has been reported with combination therapy in patients with CLL. Ongoing research is focusing on developing options for chemotherapy-free treatment and on new combinations of obinutuzumab with novel targeted agents.

引用

页码：324 / 356

页数：33

共 114 条

[1] Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies [J].